Since the original version of this article was published in 2023, the market has continued to be tight for biotech investment. New companies continue to form and get funding, but overall, investors are reducing risk with an increasing preference for companies with clinical data – or at a minimum validation in animal studies – before follow-on investments are attractive. 

GentiBio CEO Adel Nada discusses why biotechs should build organizations that allow the kind of “good” failures necessary for striking into the unknown and forming the foundations of success. To do so, we must foster cultures that prepare us for, and prepare us to learn from, the field’s inevitable setbacks.

The biotech job market is hotter than ever and it’s not likely to cool down in 2022. So if you’re thinking about joining the Great Resignation and jumping into a new role at a biotech startup, it’s crucial to learn how to think about valuing competing equity offers.